JP2018510865A5 - - Google Patents

Download PDF

Info

Publication number
JP2018510865A5
JP2018510865A5 JP2017547497A JP2017547497A JP2018510865A5 JP 2018510865 A5 JP2018510865 A5 JP 2018510865A5 JP 2017547497 A JP2017547497 A JP 2017547497A JP 2017547497 A JP2017547497 A JP 2017547497A JP 2018510865 A5 JP2018510865 A5 JP 2018510865A5
Authority
JP
Japan
Prior art keywords
antibody
cancer
fully human
seq
psma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017547497A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510865A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/021672 external-priority patent/WO2016145139A1/en
Publication of JP2018510865A publication Critical patent/JP2018510865A/ja
Publication of JP2018510865A5 publication Critical patent/JP2018510865A5/ja
Pending legal-status Critical Current

Links

JP2017547497A 2015-03-10 2016-03-10 Psmaに結合する抗体医薬 Pending JP2018510865A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562131227P 2015-03-10 2015-03-10
US62/131,227 2015-03-10
PCT/US2016/021672 WO2016145139A1 (en) 2015-03-10 2016-03-10 Antibody therapeutics that bind psma

Publications (2)

Publication Number Publication Date
JP2018510865A JP2018510865A (ja) 2018-04-19
JP2018510865A5 true JP2018510865A5 (enExample) 2019-04-11

Family

ID=56879307

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017547497A Pending JP2018510865A (ja) 2015-03-10 2016-03-10 Psmaに結合する抗体医薬

Country Status (12)

Country Link
US (2) US10100126B2 (enExample)
EP (1) EP3268039B1 (enExample)
JP (1) JP2018510865A (enExample)
KR (1) KR20180012740A (enExample)
CN (1) CN108025063A (enExample)
AR (1) AR104484A1 (enExample)
AU (1) AU2016229087A1 (enExample)
CA (1) CA2979219A1 (enExample)
IL (1) IL254310A0 (enExample)
MX (1) MX2017011600A (enExample)
TW (1) TW201639891A (enExample)
WO (1) WO2016145139A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3050085A1 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
CA3058267C (en) * 2017-03-30 2023-07-25 Progastrine Et Cancers S.A R.L. Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
CA3056261A1 (en) 2017-04-07 2018-10-11 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
US12391758B2 (en) 2018-08-20 2025-08-19 1Globe Biomedical Co., Ltd. Anti-PD-L1 cancer immunotherapy antibodies
PH12022551426A1 (en) * 2020-01-06 2023-11-20 Cytomx Therapeutics Inc Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof
CN111303288B (zh) * 2020-03-04 2020-12-25 和铂医药(苏州)有限公司 一种分离的结合抗原psma的蛋白及其用途
IL299748A (en) 2020-07-08 2023-03-01 Lava Therapeutics N V Antibodies that bind PSMA and T gamma delta receptors
CN112480260B (zh) * 2020-12-09 2022-03-08 福州迈新生物技术开发有限公司 抗psma蛋白单克隆抗体、细胞系及其制备方法和应用
JP2026507228A (ja) 2023-03-03 2026-02-27 アーセナル バイオサイエンシズ インコーポレイテッド Psma及びca9を標的とするシステム

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE19728697C1 (de) 1997-07-04 1999-03-25 Deutsches Krebsforsch Humaner Antikörper gegen ein Fusions(poly)peptid bzw. -protein, das einen Anteil von mindestens sechs Histidinen aufweist
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6938003B2 (en) 2000-06-30 2005-08-30 Mahesh Harpale Method and apparatus for a credibility reporting system to augment an online exchange
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
KR20040077889A (ko) * 2002-01-28 2004-09-07 메다렉스, 인코포레이티드 전립선 특이적 막 항원 (psma)에 대한 인간모노클로날 항체
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
MX2007009878A (es) * 2005-02-18 2007-10-03 Medarex Inc Anticuerpos monoclonales para antigeno de membrana especifica para prostata (amep).
CN101160324B (zh) * 2005-02-18 2013-04-24 米德列斯公司 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP2281004A4 (en) * 2008-04-14 2012-02-15 Proscan Rx Pharma Inc PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
WO2010054007A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
EP2419451A4 (en) * 2009-04-14 2012-11-14 Proscan Rx Pharma Inc ANTIBODIES DIRECTED AGAINST THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN
EP2496600A1 (en) * 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
CN103333249A (zh) * 2013-06-14 2013-10-02 广州康合生物科技有限公司 一种抗前列腺特异性膜抗原(psma)的单克隆抗体及其应用
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения

Similar Documents

Publication Publication Date Title
JP2021054859A5 (enExample)
JP2018510147A5 (enExample)
JP2018510151A5 (enExample)
JP2018508509A5 (enExample)
JP2019214586A5 (enExample)
JP2016521692A5 (enExample)
PE20220142A1 (es) Anticuerpos de cadena pesada que se unen al psma
SA523440043B1 (ar) أجسام مضادة ضد cd3 إبسيلون جديدة
RU2016150377A (ru) Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc
JP2012116856A5 (enExample)
JP2018504907A5 (enExample)
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
JP2017176174A5 (enExample)
PE20190737A1 (es) Anticuerpos anti-cd27
WO2016191246A3 (en) T cell receptor-like antibodies specific for a prame peptide
EA201890302A1 (ru) Химерные рецепторы антигенов на основе однодоменных антител и способы их применения
HRP20241381T1 (hr) Nova anti-pd-1 protutijela
JP2017506649A5 (enExample)
JP2016512223A5 (enExample)
MX2014002097A (es) Anticuerpos bioespecificos especificos para antigenos que activan celulas t y un antigeno tumoral y metodos de uso.
JP2014509837A5 (enExample)
CO6612264A2 (es) Proteinas terapeuticas de la union a dll 4
RU2020142534A (ru) Композиция для лечения рака, объединяющая анти-cd26 антитело и другое противораковое средство
JP2017518260A5 (enExample)